SAN DIEGO , May 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has initiated sites for its ELEVATE UC Phase 3 global program to evaluate etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC). Arena will pr…